# Masataka Suzuki

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9137587/publications.pdf

Version: 2024-02-01

| 28 | 996 | 471509 17 | 501196 28 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 28 | 28 | 28 | 1270 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Armed Oncolytic Adenovirusâ€“Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 2017, 77, 2040-2051. | 0.9 | 170 |
| 2 | Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Molecular Therapy, 2017, 25, 2440-2451. | 8.2 | 151 |
| 3 | Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Molecular Therapy, 2020, 28, 1251-1262. | 8.2 | 89 |
| 4 | Recent advances in oncolytic adenovirus therapies for cancer. Current Opinion in Virology, 2016, 21, 9-15. | 5.4 | 77 |
| 5 | Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Frontiers in Immunology, 2018, 9, 2103. | 4.8 | 56 |
| 6 | Immunology of Adenoviral Vectors in Cancer Therapy. Molecular Therapy - Methods and Clinical Development, 2019, 15, 418-429. | 4.1 | 54 |
| 7 | Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 2021, 29, 505-520. | 8.2 | 48 |
| 8 | Differential Type I Interferon-dependent Transgene Silencing of Helper-dependent Adenoviral vs. Adeno-associated Viral Vectors In Vivo. Molecular Therapy, 2013, 21, 796-805. | 8.2 | 40 |
| 9 | Large-Scale Production of High-Quality Helper-Dependent Adenoviral Vectors Using Adherent Cells in Cell Factories. Human Gene Therapy, 2010, 21, 120-126. | 2.7 | 35 |
| 10 | Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Molecular Therapy, 2021, 29, 1808-1820. | 8.2 | 34 |
| 11 | MyD88-Dependent Silencing of Transgene Expression During the Innate and Adaptive Immune Response to Helper-Dependent Adenovirus. Human Gene Therapy, 2010, 21, 325-336. | 2.7 | 31 |
| 12 | Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Molecular Therapy, 2015, 23, 1497-1506. | 8.2 | 28 |
| 13 | Early STAT1 Activation After Systemic Delivery of HSV Amplicon Vectors Suppresses Transcription of The Vector-encoded Transgene. Molecular Therapy, 2007, 15, 2017-2026. | 8.2 | 27 |
| 14 | Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. Human Gene Therapy, 2012, 23, 1065-1070. | 2.7 | 25 |
| 15 | Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Communications Biology, 2021, 4, 368. | 4.4 | 23 |
| 16 | NOD2 Signaling Contributes to the Innate Immune Response Against Helper-Dependent Adenovirus Vectors Independently of MyD88 In Vivo. Human Gene Therapy, 2011, 22, 1071-1082. | 2.7 | 22 |
| 17 | Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics, 2014, 1, 14008. | 4.4 | 19 |
| 18 | Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. Molecular Genetics and Metabolism, 2016, 117, 378-382. | 1.1 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers, 2020, 12, 619. | 3.7 | 11 |
| 20 | Engineering oncolytic vaccinia virus to redirect macrophages to tumor cells. Advances in Cell and Gene Therapy, 2021, 4, e99. | 0.9 | 10 |
| 21 | HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers, 2022, 14, 2769. | 3.7 | 8 |
| 22 | Current development in adenoviral vectors for cancer immunotherapy. Molecular Therapy - Oncolytics, 2021, 23, 571-581. | 4.4 | 7 |
| 23 | Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies. Molecular Therapy, 2017, 25, 836-838. | 8.2 | 4 |
| 24 | Three Decades of Clinical Gene Therapy: From Experimental Technologies to Viable Treatments. Molecular Therapy, 2021, 29, 411-412. | 8.2 | 4 |
| 25 | Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigenâ€specific immunotherapy. Head and Neck, 2021, 43, 1983-1994. | 2.0 | 4 |
| 26 | Adenovirus Immunity: X Marks the Spot. Molecular Therapy, 2012, 20, 2197-2198. | 8.2 | 3 |
| 27 | Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. Biomedicines, 2014, 2, 110-131. | 3.2 | 3 |
| 28 | Self-Complementary AAV Vectors Cause a Substantially Heightened TLR9-Dependent Innate Immune Response In the Liver. Blood, 2010, 116, 252-252. | 1.4 | 1 |